DaVita to Pay $4.42 Billion for HealthCare Partners
DaVita Inc. (DVA), a provider of kidney dialysis care, agreed to buy HealthCare Partners for about $4.42 billion in cash and stock to expand into broader medical services. The shares rose.
DaVita will pay $3.66 billion in cash plus 9.38 million shares of its stock, which had a value of $758 million as of May 18, for HealthCare Partners, the companies said today in a statement. Closely held HealthCare Partners will run as a separate subsidiary of Denver-based DaVita once the acquisition is completed.
HealthCare Partners manages medical groups and physician networks under a system that rewards lowering health costs, said Gary Lieberman, an analyst with Wells Fargo Securities. That focus on savings and improved outcomes drew DaVita’s interest as the model is “where the puck is headed for American health care,” DaVita Chief Executive Officer Kent Thiry told analysts on a conference call today.
“Our initial take on this transformational acquisition is positive,” Kevin Ellich, an analyst with Piper Jaffray & Co., wrote in a research note. “This deal was done to provide more comprehensive care to patients as DaVita evolves into an integrated care provider.”
DaVita rose 4.9 percent to $84.80 at the close in New York, the biggest gain since October. The shares have fallen less than 1 percent in the past 12 months.
DaVita has indicated the so-called accountable care model also may be adopted in the dialysis industry, Lieberman said. In that system, insurers pay a certain amount per patient each month with the incentive for care providers to lower costs in order to make money, he said.
“Medicare or commercial payers would pay DaVita a capitated amount to take care of their patients, and the rest would be on them to do a good job,” Lieberman said in a telephone interview. “That’s where the opportunity is.”
HealthCare Partners, based in Torrance, California, provides services to more than 667,000 patients through 700 physicians employed by the company or its affiliates. The company, whose key operations are in Southern California, central Florida and southern Nevada, had revenue last year of about $2.4 billion.
The purchase price is about 8.4 times HealthCare Partners’ 2011 earnings before interest, tax, depreciation and amortization of $527 million. That compares with a median of 9.7 times Ebitda for seven deals announced in the last three years, according to data compiled by Bloomberg.
The transaction probably will close early in the fourth quarter and the combined entity will be known as DaVita HealthCare Partners Inc., the companies said. The cash portion of the purchase price will be funded through available cash, credit and debt financing, they said.
DaVita’s biggest shareholder is Warren Buffett’s Berkshire Hathaway Inc. (BRK/B), which has a 6.4 percent stake, according to data compiled by Bloomberg. Omaha, Nebraska-based Berkshire reported in March that it had more than doubled the number of shares it owns in the first three months of the year.
DaVita has purchased companies in the U.S., Germany and India to meet rising demand for dialysis services as the number of people with diabetes increases.
About 552 million people may have diabetes by 2030, compared with about 366 million now, if nothing is done to curb the epidemic, the Brussels-based International Diabetes Federation said in a report in November.
Diabetes results when the body is unable to properly control sugar levels in the blood. High blood sugar can stress the kidneys, causing them to stop working and leading to dialysis treatment, in which the blood is cleansed using a machine.
DaVita in April acquired a majority stake in Lehbi Care, a Saudi Arabian provider of kidney care, for an undisclosed price. Lehbi operates three dialysis clinics in Riyadh. DaVita bought NephroLife Care India Pvt., a dialysis center operator, in January.
Last year DaVita bought ExtraCorp AG, the owner of two dialysis centers in Germany, home of rival dialysis provider Fresenius Medical Care AG, for undisclosed terms. It also acquired DSI Renal Inc. in the U.S. for about $690 million. Fresenius Medical is the biggest dialysis provider in the U.S., and DaVita is the second largest.
DaVita operated or provided administration for 1,809 dialysis facilities in the U.S., serving about 142,000 patients, it said in April. At the time, the company operated 11 outpatient dialysis centers in three other countries.
JP Morgan Securities LLC served as financial adviser and Morrison & Forrester LLP served as lead counsel on the transaction, while Sheppard Mullin Richter & Hampton LLP worked as regulatory counsel to DaVita. Munger, Tolles & Olson LLP and Nossaman LLP served as legal advisers to HealthCare Partners.
Peter Grauer, the chairman of Bloomberg LP, the parent company of Bloomberg News, has served on DaVita’s board of directors since 1994.
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.